Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Description

This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.

Conditions

Pancreatic Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.

A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Condition
Pancreatic Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Stanford University, School of Medicine, Palo Alto, California, United States, 94304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma
  • * Planned standard of care surgery with curative intent for pancreatic adenocarcinoma
  • * Life expectancy of more than 12 weeks
  • * Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level =\< 1
  • * Hemoglobin \>= 9 gm/dL
  • * Platelet count \>= 100,000/mm\^3
  • * Magnesium \> the lower limit of normal per institution normal lab values
  • * Potassium \> the lower limit of normal per institution normal lab values
  • * Calcium \> the lower limit of normal per institution normal lab values
  • * Thyroid-stimulating hormone (TSH) \< 13 micro international units/mL
  • * Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
  • * Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment
  • * History of infusion reactions to panitumumab or other monoclonal antibody therapies
  • * Pregnant or breastfeeding
  • * Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 460 ms in females)
  • * Lab values that in the opinion of the physician would prevent surgical resection
  • * Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents

Ages Eligible for Study

19 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eben Rosenthal,

George Poultsides, PRINCIPAL_INVESTIGATOR, Stanford University

Eben Rosenthal, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2027-09